TTA-A2 is a selective T-type calcium channel antagonist as a potent anticonvulsant that the Cav3.1 isoform plays a prominent role in mediating. TTA-A2 is equally potent against the Cav3.1 (a1G) and Cav3.2 (a1H) channels with IC50 values of 89 nM and 92 nM, respectively, at -80 and -100 mV holding potentials. TTA-A2 can be used for the research of a variety of human neurological diseases, including sleep disorders and epilepsy.

Cav 3.1 (a1G):89 nM, Cav 3.2 (a1H):92 nM

TTA-A2（口腔灌胃；10 mg/kg；每日一次；连续5天）在调节复发性丘脑皮质网络活动上显示出选择性效应，它能在野生型小鼠中抑制活跃觉醒并促进慢波睡眠，但在缺乏Cav3.1与Cav3.3的小鼠中不产生这些效应[1]。TTA-A2（口腔灌胃；3 mg/kg；单剂量）在大鼠中对睡眠架构产生显著影响，用药后不久活跃觉醒减少，同时增加delta睡眠并减少REM睡眠。此外，这些效果在大鼠中可持续至少4小时[2]。